205 related articles for article (PubMed ID: 26475093)
1. Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.
Wu Z; Bai F; Fan L; Pang W; Han R; Wang J; Liu Y; Yan X; Duan H; Xing L
Hum Pathol; 2015 Dec; 46(12):1935-44. PubMed ID: 26475093
[TBL] [Abstract][Full Text] [Related]
2. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
[TBL] [Abstract][Full Text] [Related]
3. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.
Sato K; Suda K; Shimizu S; Sakai K; Mizuuchi H; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
PLoS One; 2016; 11(4):e0154186. PubMed ID: 27100677
[TBL] [Abstract][Full Text] [Related]
5. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A
Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492
[TBL] [Abstract][Full Text] [Related]
6. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
7. Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.
Huang KY; Wang TH; Chen CC; Leu YL; Li HJ; Jhong CL; Chen CY
Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572484
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
[TBL] [Abstract][Full Text] [Related]
9. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
[TBL] [Abstract][Full Text] [Related]
10. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
11. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
[TBL] [Abstract][Full Text] [Related]
13. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
[TBL] [Abstract][Full Text] [Related]
14. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
16. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
17. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
[TBL] [Abstract][Full Text] [Related]
18. [Epidermal growth factor receptor (EGFR) mutation status before and after acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma].
Ye SB; Li R; Shi SS
Zhonghua Bing Li Xue Za Zhi; 2017 Feb; 46(2):98-101. PubMed ID: 28173668
[No Abstract] [Full Text] [Related]
19. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
20. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]